Pharmacokinetic Study of Yohimbine and Its Pharmacodynamic Effects on Salivary Secretion in Patients Treated with Tricyclic Antidepressants

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1994 Jan 1

PMID 8148228

Citations 2

Authors

H Bagheri

P Picault

L Schmitt

G Houin

M Berlan

J L Montastruc

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetic parameters and the time course of the effect after acute oral administration of yohimbine on salivary secretion in patients treated with tricyclic antidepressants were investigated. Yohimbine (10 mg) increased both salivary outflow and plasma noradrenaline levels for 4 h. Pharmacokinetic parameters (t1/2, tmax, Cmax and AUCexp) and plasma concentrations of noradrenaline were higher in patients treated with tricyclic antidepressants than in controls. At this dose, yohimbine induced a relatively large number of side effects. A lower dose (4 mg) increased salivary secretion for 3 h without any side effects in patients treated with tricyclic antidepressants but not in healthy volunteers. These data describe an interaction between yohimbine and tricyclic antidepressants and thus show that a relatively low dose (4 mg) of yohimbine could be useful in the treatment of dry mouth due to tricyclic antidepressants.

Citing Articles

Multifaced Nature of Yohimbine-A Promising Therapeutic Potential or a Risk?.

Nowacka A, Sniegocka M, Sniegocki M, Ziolkowska E, Bozilow D, Smuczynski W Int J Mol Sci. 2024; 25(23).

PMID: 39684567 PMC: 11641166. DOI: 10.3390/ijms252312856.

Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states.

Bryson H, Wilde M Drugs Aging. 1996; 8(6):459-76.

PMID: 8736630 DOI: 10.2165/00002512-199608060-00008.

References

Norris H . The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology. 1971; 10(21):181-91. DOI: 10.1016/0028-3908(71)90039-6. View

QUINTON R . THE INCREASE IN THE TOXICITY OF YOHIMBINE INDUCED BY IMIPRAMINE AND OTHER DRUGS IN MICE. Br J Pharmacol Chemother. 1963; 21:51-66. PMC: 1703860. DOI: 10.1111/j.1476-5381.1963.tb01501.x. View

Goldberg M, Robertson D . Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev. 1983; 35(3):143-80. View

Owen J, Nakatsu S, Condra M, SURRIDGE D, Fenemore J, Morales A . Sub-nanogram analysis of yohimbine and related compounds by high-performance liquid chromatography. J Chromatogr. 1985; 342(2):333-40. DOI: 10.1016/s0378-4347(00)84524-7. View

Owen J, Nakatsu S, Fenemore J, Condra M, SURRIDGE D, Morales A . The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol. 1987; 32(6):577-82. DOI: 10.1007/BF02455991. View

Lacomblez L, Bensimon G, Isnard F, Diquet B, Lecrubier Y, Puech A . Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine. Clin Pharmacol Ther. 1989; 45(3):241-51. DOI: 10.1038/clpt.1989.24. View

Chatelut E, Rispail Y, Berlan M, Montastruc J . Yohimbine increases human salivary secretion. Br J Clin Pharmacol. 1989; 28(3):366-8. PMC: 1379958. DOI: 10.1111/j.1365-2125.1989.tb05440.x. View

MONTASTRUC P, Berlan M, Montastruc J . Effects of yohimbine on submaxillary salivation in dogs. Br J Pharmacol. 1989; 98(1):101-4. PMC: 1854671. DOI: 10.1111/j.1476-5381.1989.tb16868.x. View

Chiba R, Isii Y . [Determination of yohimbine in serum by high performance liquid chromatography]. Yakugaku Zasshi. 1990; 110(4):289-92. DOI: 10.1248/yakushi1947.110.4_289. View

10.

Guthrie S, Hariharan M, Grunhaus L . Yohimbine bioavailability in humans. Eur J Clin Pharmacol. 1990; 39(4):409-11. DOI: 10.1007/BF00315421. View

11.

Rispail Y, Schmitt L, Berlan M, Montastruc J, MONTASTRUC P . Yohimbine increases salivary secretion in depressed patients treated with tricyclic antidepressants. Eur J Clin Pharmacol. 1990; 39(4):425-6. DOI: 10.1007/BF00315426. View

12.

Senard J, Valet P, Durrieu G, Berlan M, Tran M, Montastruc J . Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest. 1990; 20(6):613-9. DOI: 10.1111/j.1365-2362.1990.tb01909.x. View

13.

Girolami J, Bascands J, Pecher C, Berlan M, Montastruc J, MONTASTRUC P . Yohimbine increases submaxillary kallikrein release into the saliva in dogs: evidence for alpha 2-adrenoceptor-mediated inhibition of cholinergic pathways. Br J Pharmacol. 1991; 102(2):351-4. PMC: 1918049. DOI: 10.1111/j.1476-5381.1991.tb12177.x. View

14.

Berlan M, Galitzky J, Riviere D, Foureau M, Tran M, Flores R . Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obes. 1991; 15(5):305-15. View

15.

Le Verge R, Le Corre P, Chevanne F, Doe De Maindreville M, Royer D, Levy J . Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. J Chromatogr. 1992; 574(2):283-92. DOI: 10.1016/0378-4347(92)80041-n. View

16.

Berlan M, Montastruc J, Lafontan M . Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy. Trends Pharmacol Sci. 1992; 13(7):277-82. DOI: 10.1016/0165-6147(92)90085-k. View

17.

Bagheri H, Schmitt L, Berlan M, Montastruc J . Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants. Br J Clin Pharmacol. 1992; 34(6):555-8. PMC: 1381460. DOI: 10.1111/j.1365-2125.1992.tb05661.x. View

18.

Hedner T, Edgar B, Edvinsson L, Hedner J, Persson B, Pettersson A . Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. Eur J Clin Pharmacol. 1992; 43(6):651-6. DOI: 10.1007/BF02284967. View

19.

Berlan M, Le Verge R, Galitzky J, Le Corre P . Alpha 2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine. Br J Pharmacol. 1993; 108(4):927-32. PMC: 1908160. DOI: 10.1111/j.1476-5381.1993.tb13488.x. View

20.

Blackwell B, Stefopoulos A, Enders P, Kuzma R, Adolphe A . Anticholinergic activity of two tricyclic antidepressants. Am J Psychiatry. 1978; 135(6):722-4. DOI: 10.1176/ajp.135.6.722. View